Compounds > dalteparin

dalteparin and refludan

dalteparin has been researched along with refludan in 11 studies

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (18.18)18.2507
2000's6 (54.55)29.6817
2010's3 (27.27)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Breuer, HW; Greinacher, A; Müller, R1
Turpie, AG1
Busch, C; Koch, P; Reinhold, S1
Büning, H; Gerner, FM; Hacker, UT; Hallek, M; Hutter, M; Reichenspurner, H; Stangl, M1
Dager, WE; White, RH1
Din, JN; Fox, KA; Harding, SA; Josephs, DH; Newby, DE; Sarma, J1
Antonijevic, NM; Djokic, M; Djordjevic, V; Kovac, M; Mikovic, D; Miljic, P; Mrdovic, I; Nikolic, A; Perunicic, J; Vasiljevic, Z1
Ansell, JE; Dinwoodey, DL1
Cei, M; Mumoli, N1
Budde, U; Hainmann, I; Karow, A; Mueller, C; Nakamura, L; Zieger, B1
Bereczky, Z; Boda, Z; Kappelmayer, J; Kerenyi, A; Olah, Z; Szarvas, M1

Reviews

2 review(s) available for dalteparin and refludan

ArticleYear
Anticoagulants in acute coronary syndromes.
    The American journal of cardiology, 1999, Sep-02, Volume: 84, Issue:5A

    Topics: Acute Disease; Angina, Unstable; Anticoagulants; Aspirin; Clinical Trials as Topic; Coronary Disease; Dalteparin; Enoxaparin; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Hirudin Therapy; Hirudins; Humans; Myocardial Infarction; Recombinant Proteins

1999
Heparins, low-molecular-weight heparins, and pentasaccharides: use in the older patient.
    Cardiology clinics, 2008, Volume: 26, Issue:2

    Topics: Aged; Anticoagulants; Arginine; Enoxaparin; Fondaparinux; Heparin; Heparin, Low-Molecular-Weight; Hirudins; Humans; Pipecolic Acids; Polysaccharides; Recombinant Proteins; Sulfonamides

2008

Other Studies

9 other study(ies) available for dalteparin and refludan

ArticleYear
[Heparin-induced thrombocytopenia type II].
    Deutsche medizinische Wochenschrift (1946), 1999, Jan-22, Volume: 124, Issue:3

    Topics: Aged; Anticoagulants; Appendectomy; Female; Fibrinolytic Agents; Hirudin Therapy; Hirudins; Humans; Nadroparin; Perioperative Care; Phenprocoumon; Recombinant Proteins; Thrombocytopenia

1999
Delayed allergic skin reactions to subcutaneous heparins. Tolerance of 2 recombinant hirudins.
    Contact dermatitis, 2000, Volume: 42, Issue:5

    Topics: Anticoagulants; Cross Reactions; Dalteparin; Drug Hypersensitivity; Female; Hirudins; Humans; Hypersensitivity, Delayed; Middle Aged; Nadroparin; Recombinant Proteins; Skin Tests

2000
Standard heparin, low molecular weight heparin, low molecular weight heparinoid, and recombinant hirudin differ in their ability to inhibit transduction by recombinant adeno-associated virus type 2 vectors.
    Gene therapy, 2001, Volume: 8, Issue:12

    Topics: Anticoagulants; Chondroitin Sulfates; Dependovirus; Dermatan Sulfate; Dose-Response Relationship, Drug; Drug Combinations; Genetic Vectors; HeLa Cells; Heparin; Heparin, Low-Molecular-Weight; Heparitin Sulfate; Hirudins; Humans; Recombinant Proteins; Tinzaparin; Transduction, Genetic

2001
Low-molecular-weight heparin-induced thrombocytopenia in a child.
    The Annals of pharmacotherapy, 2004, Volume: 38, Issue:2

    Topics: Anticoagulants; Child; Enoxaparin; Female; Heparin, Low-Molecular-Weight; Hirudins; Humans; Platelet Count; Recombinant Proteins; Thrombocytopenia

2004
Promotion of proinflammatory interactions between platelets and monocytes by unfractionated heparin.
    Heart (British Cardiac Society), 2006, Volume: 92, Issue:11

    Topics: Adult; Anticoagulants; Cell Aggregation; Enoxaparin; Heparin; Hirudins; Humans; Monocytes; P-Selectin; Peptide Fragments; Platelet Aggregation; Recombinant Proteins; Thrombin

2006
Clinical challenge: heparin-induced thrombocytopenia type II (HIT II) or pseudo-HIT in a patient with antiphospholipid syndrome.
    Journal of thrombosis and thrombolysis, 2008, Volume: 26, Issue:2

    Topics: Administration, Oral; Adult; Antibodies; Anticoagulants; Antiphospholipid Syndrome; Diagnosis, Differential; Factor V; Heparin; Hirudins; Humans; Infusions, Intravenous; Male; Mutation; Nadroparin; Platelet Count; Recombinant Proteins; Thrombocytopenia; Venous Thromboembolism

2008
Heparin-induced thrombocytopenia associated with pulmonary embolism.
    Clinical cardiology, 2010, Volume: 33, Issue:2

    Topics: Aged; Antibodies; Female; Fibrinolytic Agents; Fractures, Bone; Hirudins; Humans; Nadroparin; Orthopedic Procedures; Platelet Count; Pulmonary Embolism; Recombinant Proteins; Thrombocytopenia; Tomography, X-Ray Computed; Treatment Outcome

2010
Progressive thrombosis in a 13-year-old girl with trisomy 21 under therapy with low molecular weight heparin.
    Klinische Padiatrie, 2011, Volume: 223, Issue:3

    Topics: Adolescent; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Antithrombins; beta 2-Glycoprotein I; Diagnosis, Differential; Disease Progression; Dose-Response Relationship, Drug; Down Syndrome; Enoxaparin; Female; Hirudins; Humans; Immunoglobulin M; Recombinant Proteins; Renal Veins; Thrombophlebitis; Thrombosis; Vena Cava, Inferior

2011
Direct thrombin inhibitors and factor xa inhibitors can influence the diluted prothrombin time used as the initial screen for lupus anticoagulant.
    Archives of pathology & laboratory medicine, 2013, Volume: 137, Issue:7

    Topics: Anticoagulants; Antithrombins; Arginine; Chondroitin Sulfates; Dermatan Sulfate; Enoxaparin; Factor Xa Inhibitors; False Positive Reactions; Fondaparinux; Heparitin Sulfate; Hirudins; Humans; Lupus Coagulation Inhibitor; Mass Screening; Pipecolic Acids; Polysaccharides; Prothrombin Time; Recombinant Proteins; Sulfonamides; Thrombin

2013